IT1275571B - Substrati fluorogenici suscettibili di fotoattivazione previa trasformazione per via enzimatica atti alla diagnosi ed alla terapia fotodinamica dei tumori - Google Patents

Substrati fluorogenici suscettibili di fotoattivazione previa trasformazione per via enzimatica atti alla diagnosi ed alla terapia fotodinamica dei tumori

Info

Publication number
IT1275571B
IT1275571B ITMI951560A ITMI951560A IT1275571B IT 1275571 B IT1275571 B IT 1275571B IT MI951560 A ITMI951560 A IT MI951560A IT MI951560 A ITMI951560 A IT MI951560A IT 1275571 B IT1275571 B IT 1275571B
Authority
IT
Italy
Prior art keywords
photoactivation
diagnosis
cancer therapy
fluorogenic substrates
enzymatic transformation
Prior art date
Application number
ITMI951560A
Other languages
English (en)
Inventor
Giovanni Bottiroli
Anna Cleta Croce
Piero Baglioni
Monica Monici
Original Assignee
Consiglio Nazionale Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Ricerche filed Critical Consiglio Nazionale Ricerche
Priority to ITMI951560A priority Critical patent/IT1275571B/it
Publication of ITMI951560A0 publication Critical patent/ITMI951560A0/it
Priority to CA002227212A priority patent/CA2227212A1/en
Priority to AU67351/96A priority patent/AU6735196A/en
Priority to PCT/EP1996/003201 priority patent/WO1997003697A2/en
Priority to US09/011,347 priority patent/US6036941A/en
Priority to EP96927559A priority patent/EP0839051A1/en
Publication of ITMI951560A1 publication Critical patent/ITMI951560A1/it
Application granted granted Critical
Publication of IT1275571B publication Critical patent/IT1275571B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ITMI951560A 1995-07-19 1995-07-19 Substrati fluorogenici suscettibili di fotoattivazione previa trasformazione per via enzimatica atti alla diagnosi ed alla terapia fotodinamica dei tumori IT1275571B (it)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ITMI951560A IT1275571B (it) 1995-07-19 1995-07-19 Substrati fluorogenici suscettibili di fotoattivazione previa trasformazione per via enzimatica atti alla diagnosi ed alla terapia fotodinamica dei tumori
CA002227212A CA2227212A1 (en) 1995-07-19 1996-07-19 Fluorogenic substrates for diagnosis and photodynamic treatment of tumours
AU67351/96A AU6735196A (en) 1995-07-19 1996-07-19 Fluorogenic substrates for diagnosis and photodynamic treatment of tumours
PCT/EP1996/003201 WO1997003697A2 (en) 1995-07-19 1996-07-19 Fluorogenic substrates for diagnosis and photodynamic treatment of tumours
US09/011,347 US6036941A (en) 1995-07-19 1996-07-19 Fluorogenic substrates for diagnosis and photodynamic treatment of tumors
EP96927559A EP0839051A1 (en) 1995-07-19 1996-07-19 Fluorogenic substrates for diagnosis and photodynamic treatment of tumours

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI951560A IT1275571B (it) 1995-07-19 1995-07-19 Substrati fluorogenici suscettibili di fotoattivazione previa trasformazione per via enzimatica atti alla diagnosi ed alla terapia fotodinamica dei tumori

Publications (3)

Publication Number Publication Date
ITMI951560A0 ITMI951560A0 (it) 1995-07-19
ITMI951560A1 ITMI951560A1 (it) 1997-01-19
IT1275571B true IT1275571B (it) 1997-08-07

Family

ID=11372009

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI951560A IT1275571B (it) 1995-07-19 1995-07-19 Substrati fluorogenici suscettibili di fotoattivazione previa trasformazione per via enzimatica atti alla diagnosi ed alla terapia fotodinamica dei tumori

Country Status (6)

Country Link
US (1) US6036941A (it)
EP (1) EP0839051A1 (it)
AU (1) AU6735196A (it)
CA (1) CA2227212A1 (it)
IT (1) IT1275571B (it)
WO (1) WO1997003697A2 (it)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331286B1 (en) * 1998-12-21 2001-12-18 Photogen, Inc. Methods for high energy phototherapeutics
US7036516B1 (en) 1996-10-30 2006-05-02 Xantech Pharmaceuticals, Inc. Treatment of pigmented tissues using optical energy
US6493570B1 (en) * 1998-11-02 2002-12-10 Photogen, Inc. Method for improved imaging and photodynamic therapy
US7390668B2 (en) 1996-10-30 2008-06-24 Provectus Pharmatech, Inc. Intracorporeal medicaments for photodynamic treatment of disease
US8974363B2 (en) 1997-12-11 2015-03-10 Provectus Pharmatech, Inc. Topical medicaments and methods for photodynamic treatment of disease
US20090117199A1 (en) * 1998-08-06 2009-05-07 Scott Timothy C Method of treatment of cancer
US8557298B2 (en) * 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
CN1132557C (zh) * 1998-08-06 2003-12-31 福托金公司 靶向局部治疗疾病的装置
US7648695B2 (en) 1998-08-06 2010-01-19 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US6986740B2 (en) * 1998-11-02 2006-01-17 Xantech Pharmaceuticals, Inc. Ultrasound contrast using halogenated xanthenes
US7384623B1 (en) 1998-12-21 2008-06-10 Provectus Pharmatech, Inc. High energy phototherapeutic agents
US8470296B2 (en) 1998-12-21 2013-06-25 Provectus Pharmatech, Inc. Intracorporeal medicaments for high energy phototherapeutic treatment of disease
EP1131100B1 (en) * 1999-01-15 2003-03-12 Light Sciences Corporation Therapeutic compositions for metabolic bone disorders or bone metastases comprising a photosensitizer and a bisphosphonate
US6602274B1 (en) * 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
WO2000041726A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
EP1040825A1 (en) * 1999-03-11 2000-10-04 K.U. Leuven Research & Development Means for diagnosing bladder carcinoma
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
CA2395567A1 (en) * 2000-01-12 2001-07-19 Light Sciences Corporation Novel treatment for eye disease
WO2001089584A2 (en) * 2000-05-23 2001-11-29 Amersham Health As Contrast agents
GB0113899D0 (en) 2001-06-07 2001-08-01 Photocure Asa Photodynamic therapy lamp
EP1467760A2 (en) * 2002-01-23 2004-10-20 Light Sciences Corporation Systems and methods for photodynamic therapy
CN1389110A (zh) * 2002-05-10 2003-01-08 张红雨 苝醌衍生物光敏生物杀菌剂及其制法
WO2004002476A2 (en) 2002-06-27 2004-01-08 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
US7053210B2 (en) 2002-07-02 2006-05-30 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
GB0215534D0 (en) * 2002-07-04 2002-08-14 Ecole Polytech Selective photochemotherapy using oligonucleotide targeting agents
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
US20060067889A1 (en) * 2004-09-27 2006-03-30 Light Sciences Corporation Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents
CA2613439A1 (en) * 2005-06-30 2007-01-11 Bristol-Myers Squibb Pharma Company Hydrazide conjugates as imaging agents
CA2633636A1 (en) * 2005-11-15 2007-05-24 The General Hospital Corporation Photoactivatable antimicrobial agents
WO2007072800A1 (ja) * 2005-12-19 2007-06-28 The University Of Tokyo 光増感用化合物
US9358292B2 (en) 2007-04-08 2016-06-07 Immunolight, Llc Methods and systems for treating cell proliferation disorders
US20090104212A1 (en) * 2007-08-06 2009-04-23 Immunolight Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption
CL2009000393A1 (es) 2008-02-21 2010-01-04 Duke Univ Y Immunolight Llc Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
US9907976B2 (en) 2011-07-08 2018-03-06 Immunolight, Llc Phosphors and scintillators for light stimulation within a medium
CN105288619A (zh) 2008-04-04 2016-02-03 免疫之光有限责任公司 用于原位光生物调节的非侵入性系统和方法
EP2285381B1 (en) 2008-05-05 2015-12-16 The General Hospital Corporation Photoactivatable beta-lactamase substrates and analytical methods of using same
CA2724973C (en) 2008-05-20 2015-08-11 University Health Network Device and method for fluorescence-based imaging and monitoring
KR101385196B1 (ko) 2012-05-17 2014-04-14 주식회사 유니크메디케어 광 조사를 이용한 광감각제―펩타이드를 유효성분으로 포함하는 발모 개선 또는 촉진용 조성물 및 이를 이용한 방법
US9371555B2 (en) 2012-06-01 2016-06-21 Concordia Laboratories Inc. Lighting systems and methods of using lighting systems for in vitro potency assay for photofrin
JP2015522554A (ja) 2012-06-04 2015-08-06 サンコー・エナジー・インコーポレーテッド パラフィン油及び沈降防止剤を含む製剤
US20160073634A1 (en) 2012-06-22 2016-03-17 The General Hospital Corporation Beta-lactamase targeted photosensitizer for pesticide and pest detection
ES2664411T3 (es) 2013-03-15 2018-04-19 Suncor Energy Inc. Composiciones herbicidas
WO2016011534A1 (en) 2014-07-24 2016-01-28 University Health Network Collection and analysis of data for diagnostic purposes
AU2020211650B2 (en) 2019-01-25 2025-01-30 Nutrien Ag Solutions (Canada) Inc. Photosensitizer compounds, methods of manufacture and application to plants
JP7588289B2 (ja) 2019-02-15 2024-11-22 ニュートリエン・エージー・ソリューションズ・（カナダ）・インコーポレイテッド 植物の健康を増進するプロトポルフィリンｉｘ誘導体及びその使用
CN115998862B (zh) * 2021-10-21 2025-07-11 北京化工大学 肿瘤特异性酶响应的光动力治疗纳米材料及其制备与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647367A (en) * 1985-12-23 1987-03-03 Uop Inc. Antifouling agents for prevention of unwanted coke formation in reactors
FR2611141B1 (fr) * 1987-02-20 1991-02-01 Int Rech Cancer Centre Ensemble ou kit pour utilisation comme agent pour la destruction selective de cellules transformees ou tumorales
US4924009A (en) * 1987-06-03 1990-05-08 Bowling Green State University Xanthene dye complexes
US5137800A (en) * 1989-02-24 1992-08-11 Stereographics Limited Partnership Production of three dimensional bodies by photopolymerization
AU3474593A (en) * 1992-01-16 1993-08-03 New York University Hypericin treatment of vaccine agents for improved immunogenicity
WO1995006877A1 (en) * 1993-09-03 1995-03-09 Behringwerke Ag Fluorescent oxygen channeling immunoassays

Also Published As

Publication number Publication date
US6036941A (en) 2000-03-14
WO1997003697A3 (en) 1997-04-10
CA2227212A1 (en) 1997-02-06
ITMI951560A0 (it) 1995-07-19
AU6735196A (en) 1997-02-18
ITMI951560A1 (it) 1997-01-19
EP0839051A1 (en) 1998-05-06
WO1997003697A2 (en) 1997-02-06

Similar Documents

Publication Publication Date Title
ITMI951560A0 (it) Substrati fluorogenici suscettibili di fotoattivazione previa trasformazione per via enzimatica atti alla diagnosi ed alla terapia fotodinamica dei tumori
AU4473596A (en) Methods of human prostate cancer diagnosis
AU7012496A (en) Compounds and methods for treatment and diagnosis of prostate cancer
AU2189497A (en) Radiotherapy treatment using medial access transformation
NO986089L (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer og kakeksi
AU5481000A (en) Combination cancer therapy comprising adenosine and deaminase enzyme inhibitor
AU3792293A (en) Long-wavelength water soluble chlorin photosensitizers useful for photodynamic therapy and diagnosis of tumors
CA2199117A1 (en) Compounds and methods for the treatment of cancer
NO985331D0 (no) Ballong-kateter for fotodynamisk terapi
AU6626696A (en) Quinolones and their therapeutic use
AU7525596A (en) Devices and methods for radiation treatment of an internal body organ
AU4185100A (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
AU6328196A (en) Targets for breast cancer diagnosis and treatment
AU7380500A (en) Methods for treating tumors using neutron therapy
AU6379196A (en) Use of vitamin D4 derivatives for treating cancer
AU5300396A (en) Radiation enhanced gene therapy for treatment of tumors
NO20022245L (no) Onkolyttiske kombinasjoner for behandling av cancer
AU6062900A (en) Substituted indole compounds and their use for the treatment of cancer
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU1395499A (en) Methods for treatment of tumors and tumor cells using (ex vivo) activated t cells
AU8742198A (en) Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity
AU2001290949A1 (en) Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
AU2596901A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2118497A (en) A novel phototherapeutic method for treating cancer and/or dermatological diseases and conditions
AU4410296A (en) Diagnosis of and therapy for hereditary haemorrhagic telangiectasia

Legal Events

Date Code Title Description
0001 Granted